John Blakey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John Blakey has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ian P. Hall
Queens Medical Centre, Nottingham, UK
2 shared publications - Andrew John Wardlaw
University of Leicester
1 shared publication Charlotte E Bolton
University of Nottingham
1 shared publicationDavid Hodgson
University of Nottingham
1 shared publication- Gerard H. Koppelman
Department of Pediatric Pulmonology and Pediatric Allergology University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital Groningen The Netherlands
1 shared publication - Ian Sayers
Centre for Respiratory Research, NIHR Biomedical Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK
1 shared publication
Latest Publications
- 20 April 2012
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 42 (5) , 617-624
What is severe asthma?
Summary: Asthma is common, and some individuals are severely affected by it. Learned institutions have sought to provide a definition of ‘severe asthma’ to facilitate research and clinical care. This is a challenging undertaking given the difficulty in defining asthma and the lack of supportive evidence for a distinct severe asthma phenotype. In this review, we discuss the rationale for a definition of severe asthma and the relative merits of the sequential attempts that have been made to produce such a definition. The difficulty in disentangling control and severity is highlighted, as is the heterogeneity of phenotype in severe asthma, and potential for misclassification. We conclude that the search for a singular definition of severe asthma is problematic, though likely to continue. We suggest the alternative strategy of using classifiers with a specific aim related to symptoms, pathophysiology or service provision.
- 20 April 2012
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 42 (5) , 617-624
What is severe asthma?
Summary: Asthma is common, and some individuals are severely affected by it. Learned institutions have sought to provide a definition of ‘severe asthma’ to facilitate research and clinical care. This is a challenging undertaking given the difficulty in defining asthma and the lack of supportive evidence for a distinct severe asthma phenotype. In this review, we discuss the rationale for a definition of severe asthma and the relative merits of the sequential attempts that have been made to produce such a definition. The difficulty in disentangling control and severity is highlighted, as is the heterogeneity of phenotype in severe asthma, and potential for misclassification. We conclude that the search for a singular definition of severe asthma is problematic, though likely to continue. We suggest the alternative strategy of using classifiers with a specific aim related to symptoms, pathophysiology or service provision.
- Open Access
- 18 April 2012
- Published by Springer Nature in Respiratory Research
- Vol. 13 (1) , 34
Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis
Background: Lymphangioleiomyomatosis is a rare disease occurring almost exclusively in women. Diagnosis often requires surgical biopsy and the clinical course varies between patients with no predictors of progression. We evaluated recent diagnostic guidelines, clinical features and serum biomarkers as diagnostic and prognostic tools. Methods: Serum vascular endothelial growth factor-D (VEGF-D), angiotensin converting enzyme (ACE), matrix metalloproteinases (MMP) -2 and -9, clinical phenotype, thoracic and abdominal computerised tomography, lung function and quality of life were examined in a cohort of 58 patients. 32 healthy female controls had serum biomarkers measured. Results: Serum VEGF-D, ACE and total MMP-2 levels were elevated in patients. VEGF-D was the strongest discriminator between patients and controls (median = 1174 vs. 332 pg/ml p < 0.0001 with an area under the receiver operating characteristic curve of 0.967, 95% CI 0.93-1.01). Application of European Respiratory Society criteria allowed a definite diagnosis without biopsy in 69%. Adding VEGF-D measurement to ERS criteria further reduced the need for biopsy by 10%. VEGF-D was associated with lymphatic involvement (p = 0.017) but not the presence of angiomyolipomas. Conclusions: Combining ERS criteria and serum VEGF-D reduces the need for lung biopsy in LAM. VEGF-D was associated with lymphatic disease but not lung function.
- 18 April 2012
- Published by Springer Nature in Respiratory Research
- Vol. 13 (1) , 34
Open AccessClinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis
Background: Lymphangioleiomyomatosis is a rare disease occurring almost exclusively in women. Diagnosis often requires surgical biopsy and the clinical course varies between patients with no predictors of progression. We evaluated recent diagnostic guidelines, clinical features and serum biomarkers as diagnostic and prognostic tools. Methods: Serum vascular endothelial growth factor-D (VEGF-D), angiotensin converting enzyme (ACE), matrix metalloproteinases (MMP) -2 and -9, clinical phenotype, thoracic and abdominal computerised tomography, lung function and quality of life were examined in a cohort of 58 patients. 32 healthy female controls had serum biomarkers measured. Results: Serum VEGF-D, ACE and total MMP-2 levels were elevated in patients. VEGF-D was the strongest discriminator between patients and controls (median = 1174 vs. 332 pg/ml p < 0.0001 with an area under the receiver operating characteristic curve of 0.967, 95% CI 0.93-1.01). Application of European Respiratory Society criteria allowed a definite diagnosis without biopsy in 69%. Adding VEGF-D measurement to ERS criteria further reduced the need for biopsy by 10%. VEGF-D was associated with lymphatic involvement (p = 0.017) but not the presence of angiomyolipomas. Conclusions: Combining ERS criteria and serum VEGF-D reduces the need for lung biopsy in LAM. VEGF-D was associated with lymphatic disease but not lung function.
- 9 November 2011
- Published by Wiley
- No. 11
Inspiratory muscle training for chronic obstructive pulmonary disease
- 9 November 2011
- Published by Wiley
- No. 11
Inspiratory muscle training for chronic obstructive pulmonary disease
- 12 May 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 71 (6) , 824-831
Current progress in pharmacogenetics
The study of genetic variation has the potential to aid understanding of the mechanisms underlying the observed inter-individual variation in drug response and by which idiosyncratic adverse effects occur. In this review, we outline current progress in pharmacogenetics using examples to highlight both mechanisms of influence of polymorphisms and research strategies for their detection. In the final sections we discuss contemporary challenges for both researchers and clinicians.
- 12 May 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 71 (6) , 824-831
Current progress in pharmacogenetics
The study of genetic variation has the potential to aid understanding of the mechanisms underlying the observed inter-individual variation in drug response and by which idiosyncratic adverse effects occur. In this review, we outline current progress in pharmacogenetics using examples to highlight both mechanisms of influence of polymorphisms and research strategies for their detection. In the final sections we discuss contemporary challenges for both researchers and clinicians.
- Open Access
- 28 April 2008
- Published by Springer Nature in Respiratory Research
- Vol. 9 (1) , 38
Meta-analysis of genome-wide linkage studies of asthma and related traits
Background: Asthma and allergy are complex multifactorial disorders, with both genetic and environmental components determining disease expression. The use of molecular genetics holds great promise for the identification of novel drug targets for the treatment of asthma and allergy. Genome-wide linkage studies have identified a number of potential disease susceptibility loci but replication remains inconsistent. The aim of the current study was to complete a meta-analysis of data from genome-wide linkage studies of asthma and related phenotypes and provide inferences about the consistency of results and to identify novel regions for future gene discovery. Methods: The rank based genome-scan meta-analysis (GSMA) method was used to combine linkage data for asthma and related traits; bronchial hyper-responsiveness (BHR), allergen positive skin prick test (SPT) and total serum Immunoglobulin E (IgE) from nine Caucasian asthma populations. Results: Significant evidence for susceptibility loci was identified for quantitative traits including; BHR (989 pedigrees, n = 4,294) 2p12-q22.1, 6p22.3-p21.1 and 11q24.1-qter, allergen SPT (1,093 pedigrees, n = 4,746) 3p22.1-q22.1, 17p12-q24.3 and total IgE (729 pedigrees, n = 3,224) 5q11.2-q14.3 and 6pter-p22.3. Analysis of the asthma phenotype (1,267 pedigrees, n = 5,832) did not identify any region showing genome-wide significance. Conclusion: This study represents the first linkage meta-analysis to determine the relative contribution of chromosomal regions to the risk of developing asthma and atopy. Several significant results were obtained for quantitative traits but not for asthma confirming the increased phenotype and genetic heterogeneity in asthma. These analyses support the contribution of regions that contain previously identified asthma susceptibility genes and provide the first evidence for susceptibility loci on 5q11.2-q14.3 and 11q24.1-qter.
- 28 April 2008
- Published by Springer Nature in Respiratory Research
- Vol. 9 (1) , 38
Open AccessMeta-analysis of genome-wide linkage studies of asthma and related traits
Background: Asthma and allergy are complex multifactorial disorders, with both genetic and environmental components determining disease expression. The use of molecular genetics holds great promise for the identification of novel drug targets for the treatment of asthma and allergy. Genome-wide linkage studies have identified a number of potential disease susceptibility loci but replication remains inconsistent. The aim of the current study was to complete a meta-analysis of data from genome-wide linkage studies of asthma and related phenotypes and provide inferences about the consistency of results and to identify novel regions for future gene discovery. Methods: The rank based genome-scan meta-analysis (GSMA) method was used to combine linkage data for asthma and related traits; bronchial hyper-responsiveness (BHR), allergen positive skin prick test (SPT) and total serum Immunoglobulin E (IgE) from nine Caucasian asthma populations. Results: Significant evidence for susceptibility loci was identified for quantitative traits including; BHR (989 pedigrees, n = 4,294) 2p12-q22.1, 6p22.3-p21.1 and 11q24.1-qter, allergen SPT (1,093 pedigrees, n = 4,746) 3p22.1-q22.1, 17p12-q24.3 and total IgE (729 pedigrees, n = 3,224) 5q11.2-q14.3 and 6pter-p22.3. Analysis of the asthma phenotype (1,267 pedigrees, n = 5,832) did not identify any region showing genome-wide significance. Conclusion: This study represents the first linkage meta-analysis to determine the relative contribution of chromosomal regions to the risk of developing asthma and atopy. Several significant results were obtained for quantitative traits but not for asthma confirming the increased phenotype and genetic heterogeneity in asthma. These analyses support the contribution of regions that contain previously identified asthma susceptibility genes and provide the first evidence for susceptibility loci on 5q11.2-q14.3 and 11q24.1-qter.
Passing PACES
After passing your A levels and getting into medical school, you stayed sober long enough to pass more exams and become a preregistration house officer. You impressed someone enough to give you a senior house officer job, and, after immersing yourself in medical minutiae, membership of the Royal College of Physicians (MRCP) is almost in the bag. Make sure you don't fall at the final hurdle—the …
Passing PACES
After passing your A levels and getting into medical school, you stayed sober long enough to pass more exams and become a preregistration house officer. You impressed someone enough to give you a senior house officer job, and, after immersing yourself in medical minutiae, membership of the Royal College of Physicians (MRCP) is almost in the bag. Make sure you don't fall at the final hurdle—the …
- Open Access
- 1 June 2005
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 7 (3) , 481-482
Formal learning theory and nicotine dependence: Response to Balfour
- 1 June 2005
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 7 (3) , 481-482
Open AccessFormal learning theory and nicotine dependence: Response to Balfour